These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 11719967

  • 1. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Overgaard J, Horsman MR.
    Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
    [Abstract] [Full Text] [Related]

  • 2. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Horsman MR.
    Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR.
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD.
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT.
    Cancer Res; 2003 Nov 15; 63(22):7584-90. PubMed ID: 14633671
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Wilson WR, Li AE, Cowan DS, Siim BG.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):905-8. PubMed ID: 9845119
    [Abstract] [Full Text] [Related]

  • 14. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S, Kestell P, Baguley BC, Paxton JW.
    Invest New Drugs; 2002 Aug 01; 20(3):281-95. PubMed ID: 12201491
    [Abstract] [Full Text] [Related]

  • 15. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L, Ching LM, Kestell P, Baguley BC.
    Br J Cancer; 2002 Aug 12; 87(4):465-70. PubMed ID: 12177785
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST, Zwain S, Schooltink MA, Newth AL, Baguley BC, Ching LM.
    Eur J Cancer; 2003 May 12; 39(8):1176-83. PubMed ID: 12736120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.